Biological E plans to hive off non-vaccine business and sell stake

According to rating firm ICRA, BE reported revenues of Rs 2,556.8 crore in FY22, largely driven by the government's Rs 1,500-crore contract order for supplying Corbevax vaccine against Covid.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p7t2gMO
via IFTTT